Professional
Added to YB: 2026-05-25
Pitch date: 2026-05-21
BDX [neutral]
Becton, Dickinson and Company
Author Info
No bio for this author
Company Info
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Market Cap
$40.7B
Pitch Price
N/A
Price Target
230.00
Dividend
2.84%
EV/EBITDA
8.99
P/E
25.63
EV/Sales
2.57
Sector
Health Care Equipment and Supplies
Category
value
Hinde Group Portfolio Holding: Becton, Dickinson and Company
BDX (holding update): Spun off Biosciences to Waters, received $4B cash ($2B buybacks, $2B debt paydown) + $44.86/share WAT stock (sold). FY26 guide: low single-digit rev growth, $12.52-$12.72 EPS. Trading $157.23 = 8% earnings yield despite mid-single-digit organic growth potential, margin expansion via BD Excellence initiatives, high FCF conversion. 90%+ portfolio hitting growth targets; transitory headwinds clear by FY28. Fair value $230+ implies mid-high teens annualized return. Buybacks at current levels highly accretive.
Read full article (2 min)